Menopause — MCQs
On this page
What is the investigation of choice in postmenopausal bleeding?
Which of the following statements about the postmenopausal state is false?
Which of the following hormones increases during the postmenopausal period?
Which of the following statements about the benefits of hormone replacement therapy is incorrect?
Most useful investigation in a 55-year-old postmenopausal woman with diabetes mellitus and hypertension who has presented with postmenopausal bleeding is:
Menopause Indian Medical PG Practice Questions and MCQs
Question 101: What is the investigation of choice in postmenopausal bleeding?
- A. PAP smear
- B. Laparoscopy
- C. Fractional curettage
- D. Ultrasound (Correct Answer)
Explanation: ***Ultrasound*** - An initial **transvaginal ultrasound** is the investigation of choice to assess the endometrial thickness in postmenopausal bleeding. An endometrial thickness of >4-5mm often warrants further investigation. - It helps in **ruling out endometrial pathologies** like hyperplasia, polyps, or carcinoma. *PAP smear* - A **PAP smear** is a screening test for cervical cancer, not typically used to investigate postmenopausal bleeding originating from the uterus. - While it can detect some endometrial cells, it is **not sensitive** or specific enough to diagnose the cause of postmenopausal bleeding. *Laparoscopy* - **Laparoscopy** is a surgical procedure used to visualize pelvic organs and is generally employed for diagnosing and treating conditions like endometriosis, ovarian cysts, or ectopic pregnancies. - It is **not the initial investigation** for postmenopausal bleeding and is too invasive for primary diagnosis unless other methods have failed or a specific pathology is suspected. *Fractional curettage* - **Fractional curettage** involves scraping the lining of the cervix and uterus to obtain tissue samples for histological examination. - While it can be diagnostic for endometrial pathology, it is typically performed **after an initial ultrasound** has identified increased endometrial thickness or other suspicious findings, and less commonly as a standalone initial investigation.
Question 102: Which of the following statements about the postmenopausal state is false?
- A. High FSH
- B. Low LH (Correct Answer)
- C. Low estrogen
- D. High androgen
Explanation: ***Low LH*** - This statement is **FALSE** because **LH (luteinizing hormone) levels are markedly elevated** in postmenopausal women. - The drop in ovarian estrogen production removes the **negative feedback** on the pituitary, leading to **increased LH and FSH secretion**. - Both gonadotropins (LH and FSH) are characteristically **high in postmenopause**. *High FSH* - This statement is true; **FSH (follicle-stimulating hormone) levels are markedly elevated** in postmenopausal women. - The elevated FSH is a direct consequence of the **lack of negative feedback** from inhibin and estrogen produced by the ovaries. *Low estrogen* - This statement is true; **estrogen levels plummet significantly** after menopause due to the **cessation of ovarian follicular activity**. - This **estrogen deficiency** is responsible for many postmenopausal symptoms, such as hot flashes, vaginal atrophy, and bone loss. *High androgen* - While androgens are still produced by the adrenal glands and ovaries postmenopause, their **absolute levels also decline with age**. - The statement is somewhat ambiguous, but androgens do **not increase** in absolute terms; rather, the **estrogen-to-androgen ratio changes** because estrogen falls more dramatically.
Question 103: Which of the following hormones increases during the postmenopausal period?
- A. Progesterone
- B. Estrogen
- C. FSH (Correct Answer)
- D. Androgens
Explanation: ***FSH*** - In **postmenopausal women**, the ovaries no longer produce significant amounts of **estrogen** and **progesterone**. - This lack of negative feedback on the **hypothalamus** and **pituitary gland** leads to a compensatory increase in **gonadotropin-releasing hormone (GnRH)**, which, in turn, stimulates the pituitary to produce more **FSH** and to a lesser extent, **LH**. *Progesterone* - **Progesterone levels decline** significantly after menopause as ovulation ceases. - The **corpus luteum**, which produces progesterone after ovulation, is no longer formed. *Estrogen* - **Estrogen levels decline dramatically** after menopause due to the cessation of ovarian follicular activity. - This decrease in estrogen is responsible for many menopausal symptoms, such as **hot flashes** and **vaginal dryness**. *Androgens* - While **ovarian androgen production** decreases, **adrenal androgen production** (e.g., **DHEA** and **androstenedione**) continues. - However, overall **androgen levels tend to decrease slightly** but not as dramatically as estrogen or progesterone, and they do not increase.
Question 104: Which of the following statements about the benefits of hormone replacement therapy is incorrect?
- A. Reduction in colorectal cancer (20%) (Correct Answer)
- B. Improvement in urogenital atrophy
- C. Increase in bone mineral density (2-5%)
- D. 40 - 50% improvement in vasomotor symptoms
Explanation: ***Reduction in colorectal cancer (20%)*** - While the **Women's Health Initiative (WHI)** study demonstrated a reduction in colorectal cancer incidence with combined estrogen-progestin therapy, this is **NOT considered an established or recommended benefit** of HRT. - The evidence is **inconsistent** across different studies, and importantly, colorectal cancers detected in HRT users were found at **more advanced stages**. - The **risks of HRT** (increased breast cancer, cardiovascular events, venous thromboembolism) significantly **outweigh** this uncertain benefit. - This is **NOT listed as an indication** for HRT in clinical guidelines, making this statement misleading when discussing "benefits" of HRT. *Improvement in urogenital atrophy* - **Estrogen deficiency** during menopause causes **vaginal and urethral atrophy**, leading to **dyspareunia, vaginal dryness, urgency**, and **recurrent UTIs**. - **Estrogen replacement therapy** (especially local vaginal estrogen) is **highly effective** in reversing urogenital atrophy. - This is a **well-established, FDA-approved indication** for HRT. *Increase in bone mineral density (2-5%)* - **Estrogen inhibits osteoclast activity** and promotes bone formation, playing a crucial role in maintaining **bone mineral density**. - HRT produces a **significant increase in BMD (2-5%)**, helping to **prevent osteoporosis** and reduce fracture risk in postmenopausal women. - This is a **proven benefit** and approved indication for HRT, particularly for women at high risk of osteoporosis. *40-50% improvement in vasomotor symptoms* - **Vasomotor symptoms** (hot flashes and night sweats) are the **hallmark of menopause**, caused by **estrogen deficiency**. - **HRT is the most effective treatment**, reducing frequency and severity by **40-50%** or more. - This is the **primary and most important indication** for initiating HRT in symptomatic menopausal women.
Question 105: Most useful investigation in a 55-year-old postmenopausal woman with diabetes mellitus and hypertension who has presented with postmenopausal bleeding is:
- A. Pap test
- B. Endometrial biopsy (Correct Answer)
- C. Transvaginal ultrasound examination
- D. CA-125 blood test
Explanation: ***Endometrial biopsy*** - This is the **most crucial investigation** for postmenopausal bleeding to rule out **endometrial cancer** or **hyperplasia**, especially in a patient with risk factors like diabetes and hypertension. - An endometrial biopsy directly samples the **uterine lining** for histological examination, providing a definitive diagnosis of any abnormal tissue changes. *Pap test* - A Pap test, or **Papanicolaou test**, primarily screens for **cervical cancer** by examining cells from the cervix. - It is **not effective** for detecting uterine (endometrial) abnormalities or cancer, which is the main concern with postmenopausal bleeding. *Transvaginal ultrasound examination* - While useful for assessing **endometrial thickness** and identifying structural abnormalities like polyps or fibroids, it is **not diagnostic** on its own. - An abnormal ultrasound finding, such as a thickened endometrium (usually >4-5mm in postmenopausal women), would typically prompt an endometrial biopsy for definitive diagnosis. *CA-125 blood test* - **CA-125** is a tumor marker primarily used for monitoring the response to treatment in **ovarian cancer** and can be elevated in other conditions like endometriosis or fibroids. - It is **not a screening tool** for endometrial cancer and is **not specific or sensitive enough** to be the primary investigation for postmenopausal bleeding.
Practice by Chapter
Physiology of Menopause
Practice Questions
Perimenopausal Transition
Practice Questions
Menopausal Symptoms and Management
Practice Questions
Hormone Replacement Therapy
Practice Questions
Non-hormonal Management Options
Practice Questions
Osteoporosis Prevention and Management
Practice Questions
Cardiovascular Health in Menopause
Practice Questions
Urogenital Atrophy
Practice Questions
Psychological Aspects of Menopause
Practice Questions
Premature Menopause
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free